Want to see IN:ALIVUS full AI Analyst Report?
ALIVUS Stock Chart & Stats
₹920.80
-₹16.95(-1.62%)
At close: 4:00 PM EST
₹920.80
-₹16.95(-1.62%)
Day’s Range― - ―
52-Week Range₹830.00 - ₹1,415.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)7.13K
Market Cap
₹167.62B
Enterprise Value₹112.61K
Total Cash (Recent Filing)₹6.53B
Total Debt (Recent Filing)₹1.13B
Price to Earnings (P/E)27.8
Beta0.88
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)22.17
Shares Outstanding122,771,450
10 Day Avg. Volume3,315
30 Day Avg. Volume7,125
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)3.59
Price to Sales (P/S)4.69
P/FCF Ratio46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)54.28
Revenue Forecast (FY)₹28.37B
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationA >100% revenue jump in FY2026 signals material commercial traction and successful scaling of API sales. Sustained higher volumes can amortize fixed costs, support durable margin improvement, and enable long‑term customer qualification and retention across regulated markets.
Very Low LeverageAn exceptionally conservative balance sheet with minimal debt provides resilience to industry cycles and financial flexibility to fund capex, R&D or acquisitions without material refinancing risk, supporting durable operational continuity and strategic optionality.
Strong Operating MarginsSustained high operating margins reflect structural competitiveness—efficient manufacturing, scale, and product mix advantages—enabling persistent cash generation, reinvestment capacity, and buffer against price or input cost variability over the medium term.
Bears Say
Weak Cash ConversionFCF materially trailing net income indicates working capital and capex are absorbing cash despite profit growth. If persistent, weak cash conversion can limit organic reinvestment, constrain distributions, and force external funding when scaling production for new contracts.
Margin VolatilityNotable margin swings suggest exposure to product‑mix shifts, pricing pressure or raw material cost volatility. This reduces earnings predictability and makes long‑range planning, contract pricing and investment prioritization riskier for a business dependent on repeat B2B supply.
Historical Leverage SpikeA prior episode of high leverage shows the balance sheet can swing under funding stress or aggressive growth financing. That history raises governance and refinancing vigilance: management may again resort to debt if cash conversion weakens or to pursue large inorganic moves.
Glenmark Life Sciences Limited News
ALIVUS FAQ
What was Glenmark Life Sciences Limited’s price range in the past 12 months?
Glenmark Life Sciences Limited lowest stock price was ₹830.00 and its highest was ₹1415.90 in the past 12 months.
What is Glenmark Life Sciences Limited’s market cap?
Glenmark Life Sciences Limited’s market cap is ₹167.62B.
When is Glenmark Life Sciences Limited’s upcoming earnings report date?
Glenmark Life Sciences Limited’s upcoming earnings report date is Nov 05, 2026 which is in 71 days.
How were Glenmark Life Sciences Limited’s earnings last quarter?
Glenmark Life Sciences Limited released its earnings results on Jul 30, 2026. The company reported ₹13 earnings per share for the quarter, beating the consensus estimate of ₹12.1 by ₹0.9.
Is Glenmark Life Sciences Limited overvalued?
According to Wall Street analysts Glenmark Life Sciences Limited’s price is currently Overvalued.
Does Glenmark Life Sciences Limited pay dividends?
Glenmark Life Sciences Limited pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.37%. See more information on Glenmark Life Sciences Limited dividends here
What is Glenmark Life Sciences Limited’s EPS estimate?
Glenmark Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glenmark Life Sciences Limited have?
Glenmark Life Sciences Limited has 122,771,450 shares outstanding.
What happened to Glenmark Life Sciences Limited’s price movement after its last earnings report?
Glenmark Life Sciences Limited reported an EPS of ₹13 in its last earnings report, beating expectations of ₹12.1. Following the earnings report the stock price went down -2.166%.
Which hedge fund is a major shareholder of Glenmark Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:ALIVUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Life Sciences Limited
Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, production, and global commercialization of active pharmaceutical ingredients (APIs). Its market footprint spans India, Japan, Europe, and both North and Latin America, supported by substantial export operations. Alivus Life Sciences provides an extensive catalog of APIs, including olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib. These ingredients are utilized across a diverse array of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppression, respiratory and ophthalmological conditions, urology, and anti-infectives. Additionally, the company extends its expertise by offering contract development and manufacturing services (CDMO) to numerous multinational corporations and specialty pharmaceutical enterprises.
Technical Analysis
Divi's Laboratories Limited
―
Granules India Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―